{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T12:42:35Z","timestamp":1772455355369,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,11,14]],"date-time":"2015-11-14T00:00:00Z","timestamp":1447459200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1007\/s10928-015-9452-y","type":"journal-article","created":{"date-parts":[[2015,11,14]],"date-time":"2015-11-14T08:44:34Z","timestamp":1447490674000},"page":"29-43","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Model-based approaches for ivabradine development in paediatric population, part II: PK and PK\/PD assessment"],"prefix":"10.1007","volume":"43","author":[{"given":"Sophie","family":"Peign\u00e9","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvain","family":"Fouliard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Decourcelle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marylore","family":"Chenel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,11,14]]},"reference":[{"key":"9452_CR1","unstructured":"B Regulation (EC) No 1901\/2006 of the European parliament and of the council of 12 December 2006 on medicinal products for paediatric use and amending regulation (EEC) No 1768\/92, Directive 2001\/20\/EC, Directive 2001\/83\/EC and Regulation (EC) No 726\/2004. 2012. http:\/\/eur-lex.europa.eu\/LexUriServ\/site\/en\/consleg\/2006\/R\/02006R1901-20070126en.pdf . Accessed 5 Nov 2012"},{"key":"9452_CR2","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1067\/mhj.2001.119423","volume":"142","author":"JD Kay","year":"2001","unstructured":"Kay JD, Colan SD, Graham TP Jr (2001) Congestive heart failure in paediatric patients. Am Heart J 142:923\u2013928","journal-title":"Am Heart J"},{"key":"9452_CR3","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2165\/00129784-200101010-00004","volume":"1","author":"RD Ross","year":"2001","unstructured":"Ross RD (2001) Medical management of chronic heart failure in children. Am J Cardiovasc Drugs 1:37\u201344","journal-title":"Am J Cardiovasc Drugs"},{"issue":"Suppl 2","key":"9452_CR4","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1055\/s-2004-830452","volume":"53","author":"M Hoch","year":"2005","unstructured":"Hoch M, Netz H (2005) Heart failure in paediatric patients. Thorac Cardiovasc Surg 53(Suppl 2):S129\u2013S134","journal-title":"Thorac Cardiovasc Surg"},{"key":"9452_CR5","unstructured":"CDER\/FDA (2004) General clinical pharmacology considerations for pediatric studies for drugs and biological products\u2014guidance for industry. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER)"},{"issue":"2","key":"9452_CR6","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0009-9236(98)90153-9","volume":"64","author":"I Ragueneau","year":"1998","unstructured":"Ragueneau I, Laveille C, Jochemsen R, Resplandy G, Funck-Brentano C, Jaillon P (1998) Pharmacokinetic-pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers. Clin Pharmacol Ther 64(2):192\u2013203","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"9452_CR7","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0928-0987(00)00085-3","volume":"10","author":"SB Duffull","year":"2000","unstructured":"Duffull SB, Aarons L (2000) Development of a sequential linked pharmacokinetic and pharmacodynamic simulation model for ivabradine in healthy volunteers. Eur J Pharm Sci 10(4):275\u2013284","journal-title":"Eur J Pharm Sci"},{"issue":"4","key":"9452_CR8","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1023\/A:1020953107162","volume":"29","author":"S Chabaud","year":"2002","unstructured":"Chabaud S, Girard P, Nony P, Boissel JP, HERapeutic MOdeling and Simulation Group (2002) Clinical trial simulation using therapeutic effect modeling: application to ivabradine efficacy in patients with angina pectoris. J Pharmacokinet Pharmacodyn 29(4):339\u2013363","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"9452_CR9","unstructured":"Duval V, Laveille C (2005) Ivabradine and S18982 activities on heart rate: a population PK\/PD analysis http:\/\/www.page-meeting.org\/?abstract=811"},{"key":"9452_CR10","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1053\/euhj.2000.2399","volume":"22","author":"PR Rijnbeek","year":"2001","unstructured":"Rijnbeek PR, Witsenburg M, Schrama E, Hess J, Kors JA (2001) New normal limits for the paediatric electrocardiogram. Eur Heart J 22:702\u2013711","journal-title":"Eur Heart J"},{"issue":"9770","key":"9452_CR11","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(10)62226-X","volume":"377","author":"S Fleming","year":"2011","unstructured":"Fleming S, Thompson M, Stevens R, Heneghan C, Pl\u00fcddemann A, Maconochie I, Tarassenko L, Mant D (2011) Normal ranges of heart rate and respiratory rate in children from birth to 18\u00a0years of age: a systematic review of observational studies. Lancet 377(9770):1011\u20131018","journal-title":"Lancet"},{"issue":"7","key":"9452_CR12","doi-asserted-by":"crossref","first-page":"779","DOI":"10.4155\/bio.11.19","volume":"3","author":"HC Pandya","year":"2011","unstructured":"Pandya HC, Spooner N, Mulla H (2011) Dried blood spots, pharmacokinetic studies and better medicines for children. Bioanalysis 3(7):779\u2013786. doi: 10.4155\/BIO.11.19","journal-title":"Bioanalysis"},{"issue":"11","key":"9452_CR13","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.4155\/bio.10.159","volume":"2","author":"G Emmons","year":"2010","unstructured":"Emmons G, Rowland M (2010) Pharmacokinetic considerations as to when to use dried blood spot sampling. Bioanalysis 2(11):1791\u20131796. doi: 10.4155\/bio.10.159","journal-title":"Bioanalysis"},{"key":"9452_CR14","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.csda.2004.07.002","volume":"49","author":"E Kuhn","year":"2005","unstructured":"Kuhn E, Lavielle M (2005) Maximum likelihood estimation in nonlinear mixed effects models. Comput Stat Data Anal 49:1020\u20131030","journal-title":"Comput Stat Data Anal"},{"key":"9452_CR15","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s10928-006-9043-z","volume":"34","author":"M Lavielle","year":"2007","unstructured":"Lavielle M, Mentr\u00e9 F (2007) Estimation of population pharmacokinetic parameters of saquinavir in HIV patients with the MONOLIX software. J Pharmacokinet Pharmacodyn 34:229\u2013249","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"4","key":"9452_CR16","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ejps.2011.12.017","volume":"46","author":"SY Cheung","year":"2012","unstructured":"Cheung SY, Majid O, Yates JW, Aarons L (2012) Structural identifiability analysis and reparameterisation (parameter reduction) of a cardiovascular feedback model. Eur J Pharm Sci 46(4):259\u2013271. doi: 10.1016\/j.ejps.2011.12.017","journal-title":"Eur J Pharm Sci"},{"key":"9452_CR17","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/j.csda.2006.05.007","volume":"51","author":"A Samson","year":"2006","unstructured":"Samson A, Lavielle M, Mentr\u00e9 F (2006) Extension of the SAEM algorithm to left-censored data in non-linear mixed-effects model: application to HIV dynamics model. Comput Stat Data Anal 51:1562\u20131574","journal-title":"Comput Stat Data Anal"},{"issue":"2","key":"9452_CR18","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1214\/aos\/1176344136","volume":"6","author":"Gideon E Schwarz","year":"1978","unstructured":"Schwarz Gideon E (1978) Estimating the dimension of a model. Ann Stat 6(2):461\u2013464. doi: 10.1214\/aos\/1176344136","journal-title":"Ann Stat"},{"issue":"3","key":"9452_CR19","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1208\/s12248-009-9133-0","volume":"11","author":"RM Savic","year":"2009","unstructured":"Savic RM, Karlsson MO (2009) Importance of shrinkage in empirical Bayes estimates for diagnostics: problems and solutions. AAPS J 11(3):558\u2013569. doi: 10.1208\/s12248-009-9133-0","journal-title":"AAPS J"},{"key":"9452_CR20","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1038\/psp.2014.5","volume":"3","author":"FP Combes","year":"2014","unstructured":"Combes FP, Retout S, Frey N, Mentr\u00e9 F (2014) Powers of the likelihood ratio test and the correlation test using empirical Bayes estimates for various shrinkages in population pharmacokinetics. CPT Pharmacomet Syst Pharmacol 3:e109. doi: 10.1038\/psp.2014.5","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"5309","key":"9452_CR21","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1126\/science.276.5309.122","volume":"276","author":"GB West","year":"1997","unstructured":"West GB, Brown JH, Enquist BJ (1997) A general model for the origin of allometric scaling laws in biology. Science 276(5309):122\u2013126","journal-title":"Science"},{"issue":"5","key":"9452_CR22","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00003088-199630050-00001","volume":"30","author":"NH Holford","year":"1996","unstructured":"Holford NH (1996) A size standard for pharmacokinetics. Clin Pharmacokinet 30(5):329\u2013332","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"9452_CR23","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2165\/00003088-200645090-00005","volume":"45","author":"TN Johnson","year":"2006","unstructured":"Johnson TN, Rostami-Hodjegan A, Tucker GT (2006) Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet 45(9):931\u2013956","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"9452_CR24","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00467-008-0997-5","volume":"24","author":"MM Rhodin","year":"2009","unstructured":"Rhodin MM, Anderson BJ, Peters AM, Coulthard MG, Wilkins B, Cole M, Chatelut E, Grubb A, Veal GJ, Keir MJ, Holford NH (2009) Human renal function maturation: a quantitative description using weight and postmenstrual age. Pediatr Nephrol 24(1):67\u201376","journal-title":"Pediatr Nephrol"},{"key":"9452_CR25","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1007\/s11095-006-9067-5","volume":"23","author":"K Brendel","year":"2006","unstructured":"Brendel K, Comets E, Laffont C, Laveille C, Mentr\u00e9 F (2006) Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharm Res 23:2036\u20132049","journal-title":"Pharm Res"},{"issue":"2","key":"9452_CR26","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO (2011) Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 13(2):143\u2013151. doi: 10.1208\/s12248-011-9255-z Epub 2011 Feb 8","journal-title":"AAPS J"},{"issue":"6","key":"9452_CR27","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1080\/10543400802369012","volume":"18","author":"J Bertrand","year":"2008","unstructured":"Bertrand J, Comets E, Mentre F (2008) Comparison of model-based tests and selection strategies to detect genetic polymorphisms influencing pharmacokinetic parameters. J Biopharm Stat 18(6):1084\u20131102. doi: 10.1080\/10543400802369012","journal-title":"J Biopharm Stat"},{"key":"9452_CR28","unstructured":"European Medicines Agency (2006) Guideline on the role of pharmacokinetics in the development of medicinal products in the paediatric population. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003066.pdf"},{"issue":"Suppl 1","key":"9452_CR29","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00228-009-0782-9","volume":"67","author":"RF Cock De","year":"2011","unstructured":"De Cock RF, Piana C, Krekels EH, Danhof M, Allegaert K, Knibbe CA (2011) The role of population PK-PD modelling in paediatric clinical research. Eur J Clin Pharmacol 67(Suppl 1):5\u201316. doi: 10.1007\/s00228-009-0782-9","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"9452_CR30","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1365-2125.2009.03484.x","volume":"68","author":"E Manolis","year":"2009","unstructured":"Manolis E, Pons G (2009) Proposals for model-based paediatric medicinal development within the current European Union regulatory framework. Br J Clin Pharmacol 68(4):493\u2013501. doi: 10.1111\/j.1365-2125.2009.03484.x","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"9452_CR31","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s00431-006-0189-x","volume":"165","author":"BJ Anderson","year":"2006","unstructured":"Anderson BJ, Allegaert K, Holford NH (2006) Population clinical pharmacology of children: modelling covariate effects. Eur J Pediatr 165(12):819\u2013829","journal-title":"Eur J Pediatr"},{"key":"9452_CR32","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","volume":"48","author":"BJ Anderson","year":"2008","unstructured":"Anderson BJ, Holford NH (2008) Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 48:303\u2013332","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"1","key":"9452_CR33","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2133\/dmpk.24.25","volume":"24","author":"BJ Anderson","year":"2009","unstructured":"Anderson BJ, Holford NH (2009) Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet 24(1):25\u201336","journal-title":"Drug Metab Pharmacokinet"},{"issue":"2","key":"9452_CR34","doi-asserted-by":"crossref","first-page":"E475","DOI":"10.1208\/aapsj070248","volume":"7","author":"B Meibohm","year":"2005","unstructured":"Meibohm B, L\u00e4er S, Panetta JC, Barrett JS (2005) Population pharmacokinetic studies in pediatrics: issues in design and analysis. AAPS J 7(2):E475\u2013E487","journal-title":"AAPS J"},{"issue":"4","key":"9452_CR35","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2165\/00003088-200847040-00002","volume":"47","author":"M Tod","year":"2008","unstructured":"Tod M, Jullien V, Pons G (2008) Facilitation of drug evaluation in children by population methods and modelling. Clin Pharmacokinet 47(4):231\u2013243","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"9452_CR36","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1007\/s11095-013-1079-3","volume":"30","author":"FP Combes","year":"2013","unstructured":"Combes FP, Retout S, Frey N, Mentr\u00e9 F (2013) Prediction of shrinkage of individual parameters using the bayesian information matrix in non-linear mixed effect models with evaluation in pharmacokinetics. Pharmaceutical Res 30(9):2355\u20132367. doi: 10.1007\/s11095-013-1079-3","journal-title":"Pharmaceutical Res"},{"issue":"1","key":"9452_CR37","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0026-895X(25)09118-7","volume":"36","author":"T Kronbach","year":"1989","unstructured":"Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA (1989) Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 36(1):89\u201396","journal-title":"Mol Pharmacol"},{"issue":"3","key":"9452_CR38","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1093\/bja\/89.3.428","volume":"89","author":"TN Johnson","year":"2002","unstructured":"Johnson TN, Rostami-Hodjegan A, Goddard JM, Tanner MS, Tucker GT (2002) Contribution of midazolam and its 1-hydroxy metabolite to preoperative sedation in children: a pharmacokinetic-pharmacodynamic analysis. Br J Anaesth 89(3):428\u2013437","journal-title":"Br J Anaesth"},{"issue":"12","key":"9452_CR39","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1177\/00912700122012832","volume":"41","author":"MD Reed","year":"2001","unstructured":"Reed MD, Rodarte A, Blumer JL (2001) The single-dose pharmacokinetics of midazolam and its primary metabolite in pediatric patients after oral and intravenous administration. J Clin Pharmacol 41(12):1359\u20131369","journal-title":"J Clin Pharmacol"},{"key":"9452_CR40","volume-title":"Pediatric reference ranges","author":"SJ Soldin","year":"1999","unstructured":"Soldin SJ, Brugnara C, Hicks JM (1999) Pediatric reference ranges, 3rd edn. AACC Press, Washington, DC","edition":"3"},{"key":"9452_CR41","volume-title":"Current pediatric diagnosis and treatment","author":"WW Hay","year":"2000","unstructured":"Hay WW, Hayward AR, Levin MJ, Sondheimer JM (2000) Current pediatric diagnosis and treatment, 15th edn. Lange Medical Books, New York","edition":"15"}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-015-9452-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10928-015-9452-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-015-9452-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T11:54:00Z","timestamp":1748692440000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10928-015-9452-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,14]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["9452"],"URL":"https:\/\/doi.org\/10.1007\/s10928-015-9452-y","relation":{},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"value":"1567-567X","type":"print"},{"value":"1573-8744","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,14]]}}}